# The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach to Non-invasive Fetal Risk Assessment

> **NCT07643896** · — · RECRUITING · sponsor: **BillionToOne Inc.** · enrollment: 1000 (estimated)

## Conditions studied

- Pregnant Individuals
- Aneuploidy
- Down Syndrome (Trisomy 21)
- 22q11.2 Deletion Syndrome
- Trisomy 13
- Trisomy 18
- Sex Chromosome Abnormalities

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07643896
- **Lead sponsor:** BillionToOne Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-10
- **Primary completion:** 2027-12
- **Final completion:** 2028-06
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2026-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07643896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07643896, "The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach to Non-invasive Fetal Risk Assessment". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07643896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*